Scarica l'app Stockscreener
2.82
14.17%
0.35
Dopo l'orario di chiusura:
2.80
-0.02
-0.71%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché IBRX Giù?
Forum
Previsione
Immunitybio Inc Borsa (IBRX) Ultime notizie
ImmunityBio Shares Rise After 'Promising' Results From Lymphoma Treatment - MarketScreener
ImmunityBio’s Q2 Earnings Surge Due to ANKTIVA Success - StocksToTrade
Immunitybio stock soars after promising cancer therapy trial results By Investing.com - Investing.com Canada
ImmunityBio up on trial data for cell therapy (IBRX:NASDAQ) - Seeking Alpha
CD19 CAR-NK therapy shows complete responses in late-stage lymphoma - Investing.com Canada
ImmunityBio Reports Complete Responses in Non-Hodgkin Waldenstrom Lymphoma Patients with Chemotherapy-Free, First-In-Class CD19 CAR-NK Immunotherapy - Business Wire
VA Hospitals to Administer ANKTIVA® to Bladder Cancer Patients - precisionvaccinations.com
ImmunityBio shares rise 1.21% premarket after ANKTIVA treatment approval for bladder cancer. - AInvest
ImmunityBio Announces Houston’s Michael E. DeBakey VA Medical Center Is Among the First VA Hospitals to Administer ANKTIVA® to Bladder Cancer Patients - Yahoo Finance
ImmunityBio’s Shareholder Settlement Gains Preliminary Approval - The Globe and Mail
ImmunityBio Shareholder Settlement Gains Preliminary Approval, Boosting Company's Future Prospects - AInvest
Investors Can Still File Late Claims in ImmunityBio Settlement — Here’s How to Get Your Share - TradingView
Why Investors Shouldn't Be Surprised By ImmunityBio, Inc.'s (NASDAQ:IBRX) P/S - 富途牛牛
Earnings Beat: ImmunityBio, Inc. (NASDAQ:IBRX) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts - simplywall.st
Q2 2025 Revenue Up 5% YoY to $1,241mln; Raises FY23 Guidance, Innovation Target. - AInvest
ImmunityBio Q2 Earnings Show 60% Revenue Growth, $153.7 Million in Cash, and Strong Sales Momentum. - AInvest
ImmunityBio's ANKTIVA Receives Buy Rating Amid Expanding Oncology Potential and Market Growth - AInvest
ImmunityBio Reports Q2 Earnings with 60% Revenue Increase, $43M in Sales, and 246% Unit Growth - AInvest
ImmunityBio 2025 Q2 Earnings Sustained Losses Amid Strong Revenue Surge - AInvest
ImmunityBio Reports Revenue Growth Amidst Continued Investments - TipRanks
ImmunityBio: Q2 Earnings Snapshot - Norwalk Hour
ImmunityBio's Q2 Net Loss Narrows, Revenue Rises - MarketScreener
ImmunityBio’s Revenue Jumps On Bladder Cancer Drug Success - Finimize
ImmunityBio (IBRX) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
ImmunityBio: Boral Capital raises PT to $30, maintains Buy rating. - AInvest
ImmunityBio Q2 Financial Results: $92.6 Million LossNews and Statistics - IndexBox
Immunitybio Inc earnings beat, revenue topped estimates By Investing.com - Investing.com India
ImmunityBio, Inc. SEC 10-Q Report - TradingView
Earnings Flash (IBRX) ImmunityBio Posts Q2 Net Loss $0.10 a Share, vs. FactSet Est of $0.11 Loss - MarketScreener
Immunitybio Inc earnings beat, revenue topped estimates - Investing.com
ImmunityBio Q2 revenue up 60%, surpassing market estimates, on strong sales of ANKTIVA - MarketScreener
Earnings Flash (IBRX) ImmunityBio, Inc. Reports Q2 Revenue $26.4M, vs. FactSet Est of $23.1M - MarketScreener
ImmunityBio Reports Q2 Earnings Release Reflecting 60% Increase in Revenue in Q2 2025, With Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-code - Yahoo Finance
ImmunityBio (IBRX) Announces Preliminary Financial Results for the Quarter Ended June 30 - MSN
Watch for Trend Continuation in ImmunityBio Inc. Next WeekCapital Growth With Controlled Risk Picks Suggested - beatles.ru
ImmunityBio Inc. Moves Into Overbought Range Analysts CautiousReal-Time Market Sentiment Tracking Gains Momentum - metal.it
What are the technical indicators suggesting about ImmunityBio Inc.Consistent high-performance stocks - Jammu Links News
What is the dividend policy of ImmunityBio Inc. stockInvest smarter with daily stock recommendations - Jammu Links News
Is ImmunityBio Inc. a growth stock or a value stockFree Stock Market Real-Time Monitoring - Jammu Links News
How strong is ImmunityBio Inc. company’s balance sheetGet exclusive market insights for better trading - Jammu Links News
10 Best Strong Buy Penny Stocks to Buy Now - Insider Monkey
Should I hold or sell ImmunityBio Inc. stock in 2025Explosive trading growth - Jammu Links News
Immunitybio (IBRX) Targets $80 Million Capital Raise for Business Operations - MSN
What are analysts’ price targets for ImmunityBio Inc. in the next 12 monthsBuild a portfolio that stands the test of time - Jammu Links News
What are ImmunityBio Inc. company’s key revenue driversFree Stock Index Interpretation - Jammu Links News
What is ImmunityBio Inc. company’s growth strategyMassive portfolio appreciation - Jammu Links News
How many analysts rate ImmunityBio Inc. as a “Buy”Breakneck growth rates - Jammu Links News
What institutional investors are buying ImmunityBio Inc. stockInvest confidently with market-leading analysis - Jammu Links News
ImmunityBio’s Innovative Immunotherapy Trial: A Potential Game-Changer in Cancer Treatment - The Globe and Mail
1.67%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):